Rigel Stock Falls After Update From COVID-19 Program

The FDA has informed Rigel Pharmaceuticals Inc RIGL that data submitted in May from fostamatinib Phase 2 trial for COVID-19 is insufficient for an emergency use authorization (EUA).
Rigel submitted clinical data from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib for hospitalized COVID-19 patients.
The Company is currently conducting a larger Phase 3 trial evaluating fostamatinib in hospitalized COVID-19 patients.
The 308-patient trial is expected to be complete later in 2021.
Rigel said that if the Phase 3 trial meets its endpoints, it plans to resubmit the EUA application with this additional data.
Price Action: RIGL shares are down 18.40% at $3.37 during the premarket session on the last check Friday.
Related content: Benzinga's Full FDA Calendar.

Momentum93.67

GrowthNot Available

QualityNot Available

Value41.92

Short

Medium

Long